title: Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
abstract: Systemic sclerosis is a connective tissue disease in which oxidative stress represents an important player among the complex pathogenetic mechanisms of the disease. Iloprost, an analogue of natural prostacyclin, is used in systemic sclerosis for the treatment of severe Raynaud's phenomenon and ischemic ulcers. There is a clear evidence that iloprost attenuates oxidative damage induced by ischemia-reperfusion phenomena. The aim of this study is to evaluate the effect of iloprost on oxidative status in ten patients with systemic sclerosis by measuring urinary levels of 8-isoprostaglandin-F(2alpha), a member of F(2)-isoprostanes. We found that systemic sclerosis patients cyclically treated with iloprost showed increased urinary level of 8-isoprostaglandin-F(2alpha )in comparison with healthy subjects; urinary 8-isoprostaglandin-F(2alpha) did not diminish soon after the iloprost infusion as well as 3, 15 and 30 days after the drug administration. Unlike experimental studies, in vivo the strong vasodilator effect of iloprost infusion did not reduce oxidative status.
authors: Department of Clinical and Experimental Medicine, University of Verona, P.le LA Scuro 10, 37134, Verona, Italy. reumatologia@sacrocuore.it
authors: Alessandro
authors: A
authors: Volpe
authors: Domenico
authors: D
authors: Biasi
authors: Paola
authors: P
authors: Caramaschi
authors: Lisa Maria
authors: LM
authors: Bambara
authors: Antonio
authors: A
authors: Carletto
authors: Maurizio
authors: M
authors: Degan
authors: Pietro
authors: P
authors: Minuz
mesh_terms: D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D014665:Vasodilator Agents; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D016285:Iloprost
references: Prostaglandins Other Lipid Mediat. 2001 Jun;65(2-3):73-83
references: 11403500
references: Prostaglandins Leukot Essent Fatty Acids. 2006 Jun;74(6):373-8
references: 16687243
references: Rheumatology (Oxford). 2006 Mar;45(3):314-20
references: 16219641
references: Br J Pharmacol. 1989 Oct;98(2):678-84
references: 2479443
references: Joint Bone Spine. 2006 Jan;73(1):57-61
references: 16253538
references: N Engl J Med. 2006 Jun 22;354(25):2667-76
references: 16790699
references: Clin Exp Rheumatol. 1997 Mar-Apr;15(2):135-41
references: 9196864
references: Ann Rheum Dis. 1992 Oct;51(10):1143-8
references: 1332633
references: J Cardiovasc Surg (Torino). 2002 Oct;43(5):693-6
references: 12386586
references: Cochrane Database Syst Rev. 2000;(2):CD000953
references: 10796395
references: Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):279-86
references: 15591226
references: N Engl J Med. 1985 Jan 17;312(3):159-63
references: 2981404
references: Eur J Med Res. 2006 Jul 31;11(7):295-9
references: 16899424
references: Arthritis Rheum. 2002 May;46(5):1319-23
references: 12115239
references: Arthritis Rheum. 2001 Nov;44(11):2653-64
references: 11710721
references: J Am Acad Dermatol. 1993 Jan;28(1):78-85
references: 8425975
references: J Rheumatol. 1994 Aug;21(8):1477-83
references: 7983650